Melanoma PDX Models
Melanoma is the least common, yet most deadly form of skin cancer and requires predictive research models such as patient-derived xenografts (PDX) for preclinical evaluation of new cancer treatments. PDX models maintain a true representation of human heterogeneity and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. The CrownBio melanoma PDX collection contains over 200 models including metastatic and primary disease models with clinically relevant mutations e.g. BRAF(V600E). More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.